Recommendation for Novartis’ chronic myeloid leukaemia STAMP inhibitor
Chronic myeloid leukaemia therapy Scemblix receives NICE final draft recommendation in Britain
Read More
Tag: STAMP
Novartis’ CML drug hits PhIII targets
Asciminib was superior to bosutinib in inducing a major molecular response
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
